Hildred Capital Management (Hildred), a New York based private equity firm, has closed its first institutional fund, Hildred Equity Partners II with total commitments of USD362.5 million, exceeding its target.
Hildred will continue to focus on generating strong financial returns for its partners by tapping into secular growth opportunities in attractive healthcare sectors such as consumer products, medical provider services, pharmaceuticals services, information technology, life science tools and diagnostics, as well as related businesses, and will pursue both majority and influential minority investments.
The Fund received strong support from a diverse group of both new and existing Hildred investors globally, including public pension plans, insurance companies, financial institutions, private wealth and financial services platforms, family offices, and high-net-worth individual investors. The General Partners of Hildred and their affiliated entities will invest approximately USD80 million of capital in the Fund alongside these investors.
The Fund’s leadership team includes Managing Partners David Solomon and Andrew Goldman who have been working together since 2014 and have completed many successful healthcare investments, including Crown Laboratories, Butterfly Network and Kareo.
